Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone?

BJU International

Volumn 103, Issue 5, 2009, Pages 603-608

  Schroeck, Florian R ^a,b   Aronson, William J ^c,d   Presti Jr , Joseph C ^e,f   Terris, Martha K ^g,h   Kane, Christopher J ⁱ   Amling, Christopher L ^j   Freedland, Stephen J ^a,b,k,l  

^a DUKE UNIVERSITY   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ UCSD MEDICAL CENTER   (United States)

^j Alabama   (United States)

^k DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

Aggressive recurrence; Biochemical recurrence; Predictive accuracy; Prostate cancer; PSA doubling time

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER RISK; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY;

AGED; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NOMOGRAMS; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 60449083376     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.08118.x     Document Type: Article

References (25)

1. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000 164 : 101 5
2. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001 28 : 555 65
3. D'Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998 280 : 969 74
4. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998 90 : 766 71
5. Stephenson AJ, Scardino PT, Eastham JA et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005 23 : 7005 12
6. Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis 2008 Epub ahead of print
7. Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005 173 : 1938 42
8. Moul JW, Connelly RR, Lubeck DP et al. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 2001 166 : 1322 7
9. Roberts WW, Bergstralh EJ, Blute ML et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001 57 : 1033 7
10. Chun FK, Karakiewicz PI, Briganti A et al. Prostate cancer nomograms: an update. Eur Urol 2006 50 : 914 26
11. D'Amico AV, Moul JW, Carroll PR, Sun L, Lubeck D, Chen MH. Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. J Natl Cancer Inst 2003 95 : 1376 83
12. Freedland SJ, Humphreys EB, Mangold LA et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005 294 : 433 9
13. Freedland SJ, Humphreys EB, Mangold LA et al. Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol 2007 25 : 1765 71
14. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006 176 : 1404 8
15. Freedland SJ, Amling CL, Dorey F et al. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology 2002 60 : 670 4
16. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999 281 : 1591 7
17. Cooperberg MR, Freedland SJ, Pasta DJ et al. Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer 2006 107 : 2384 91
18. R, Development-Core-Team. R: a Language and Environment for Statistical Computing. Vienna, Austria : R Foundation for Statistical Computing, 2007
19. Harrell FE. Design Package (R Package, Version 2.1-1) and Harrell Miscellaneous Package (R Package, Version 3.4-2). 2007
20. Lin DD, Schultz D, Renshaw AA, Rubin MA, Richie JP, D'Amico AV. Predictors of short postoperative prostate-specific antigen doubling time for patients diagnosed during PSA era. Urology 2005 65 : 528 32
21. Teeter AE, Banez LL, Aronson WJ et al. What are the factors associated with a short PSA doubling time? A report from the SEARCH database group. J Urol 2008 179 (Suppl. 149, Abstract 420
22. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure. J Clin Oncol 2005 23 : 4975 9
23. D'Amico AV, Chen MH, Roehl KA, Catalona WJ. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 2004 351 : 125 35
24. Ross RW, Kantoff PW. Predicting outcomes in prostate cancer: how many more nomograms do we need? J Clin Oncol 2007 25 : 3563 4
25. Roberts SG, Blute ML, Bergstralh EJ, Slezak JM, Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 2001 76 : 576 81